Cancer Research Annual Meeting 2010  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ormandy, L. A.
Right arrow Articles by Korangy, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ormandy, L. A.
Right arrow Articles by Korangy, F.
[Cancer Research 65, 2457-2464, March 15, 2005]
© 2005 American Association for Cancer Research


Immunology

Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma

Lars A. Ormandy, Tina Hillemann, Heiner Wedemeyer, Michael P. Manns, Tim F. Greten and Firouzeh Korangy

Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany

Requests for reprints: Tim F. Greten, Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany. Phone: 49-511-906-3566; Fax: 49-511-906-3534; E-mail: greten.tim{at}mh-hannover.de.

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with a poor prognosis and one for which immunotherapy remains a viable option. Experimental tumor models have shown that regulatory T cells, a functionally unique subset of T cells, can suppress effective antitumor immune responses. This suppression might explain the poor outcome of some of the immunotherapy protocols currently being used. A better understanding of the role of regulatory T cells in HCC is important for design of future immunotherapy-based clinical protocols. We have studied regulatory T cells from 84 patients with HCC and 74 controls, including healthy donors, patients with chronic hepatitis B virus and hepatitis C virus infection and nonviral liver cirrhosis. Regulatory T cells were identified by fluorescence-activated cell sorting using a panel of antibodies and by real-time PCR analysis for Foxp3 expression. Functional studies were done to analyze their inhibitory role. Finally, regulatory T cells were analyzed in tumors and ascites from patients with HCC. Patients with HCC have increased numbers of CD4+CD25+ regulatory T cells in their peripheral blood, which express high levels of HLA-DR, GITR, and low or no CD45RA. These cells were anergic toward T-cell receptor stimulation and, when cocultured with activated CD4+CD25 cells, potently suppressed their proliferation and cytokine secretion. There were also high numbers of regulatory T cells in tumor-infiltrating lymphocytes of HCC patients comparable with the increase in their peripheral blood. Our data suggest that the increase in frequency of regulatory T cells might play a role in modulation of the immune response against HCC and could be important in design of immunotherapeutic approaches.

Key Words: Hepatocellular carcinoma • regulatory T cell • immunotherapy • tumor infiltrating cells • Foxp3




This article has been cited by other articles:


Home page
J. Immunol.Home page
U. Petrausch, S. M. Jensen, C. Twitty, C. H. Poehlein, D. P. Haley, E. B. Walker, and B. A. Fox
Disruption of TGF-{beta} Signaling Prevents the Generation of Tumor-Sensitized Regulatory T Cells and Facilitates Therapeutic Antitumor Immunity
J. Immunol., September 15, 2009; 183(6): 3682 - 3689.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
D. Hirschhorn-Cymerman, G. A. Rizzuto, T. Merghoub, A. D. Cohen, F. Avogadri, A. M. Lesokhin, A. D. Weinberg, J. D. Wolchok, and A. N. Houghton
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
J. Exp. Med., May 11, 2009; 206(5): 1103 - 1116.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
K. TOKUNO, S. HAZAMA, S. YOSHINO, S. YOSHIDA, and M. OKA
Increased Prevalence of Regulatory T-Cells in the Peripheral Blood of Patients with Gastrointestinal Cancer
Anticancer Res, May 1, 2009; 29(5): 1527 - 1532.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Getnet, C. H. Maris, E. L. Hipkiss, J. F. Grosso, T. J. Harris, H.-R. Yen, T. C. Bruno, S. Wada, A. Adler, R. W. Georgantas, et al.
Tumor Recognition and Self-Recognition Induce Distinct Transcriptional Profiles in Antigen-Specific CD4 T Cells
J. Immunol., April 15, 2009; 182(8): 4675 - 4685.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
U. Svenson, B. Ljungberg, and G. Roos
Telomere Length in Peripheral Blood Predicts Survival in Clear Cell Renal Cell Carcinoma
Cancer Res., April 1, 2009; 69(7): 2896 - 2901.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
J. WADA, H. SUZUKI, R. FUCHINO, A. YAMASAKI, S. NAGAI, K. YANAI, K. KOGA, M. NAKAMURA, M. TANAKA, T. MORISAKI, et al.
The Contribution of Vascular Endothelial Growth Factor to the Induction of Regulatory T-Cells in Malignant Effusions
Anticancer Res, March 1, 2009; 29(3): 881 - 888.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. E. Ruby and A. D. Weinberg
OX40-Enhanced Tumor Rejection and Effector T Cell Differentiation Decreases with Age
J. Immunol., February 1, 2009; 182(3): 1481 - 1489.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. K. Jensen, F. Donskov, M. Nordsmark, N. Marcussen, and H. von der Maase
Increased Intratumoral FOXP3-positive Regulatory Immune Cells during Interleukin-2 Treatment in Metastatic Renal Cell Carcinoma
Clin. Cancer Res., February 1, 2009; 15(3): 1052 - 1058.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Wieczorek, A. Asemissen, F. Model, I. Turbachova, S. Floess, V. Liebenberg, U. Baron, D. Stauch, K. Kotsch, J. Pratschke, et al.
Quantitative DNA Methylation Analysis of FOXP3 as a New Method for Counting Regulatory T Cells in Peripheral Blood and Solid Tissue
Cancer Res., January 15, 2009; 69(2): 599 - 608.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H.-X. Wei, Y.-H. Chuang, B. Li, H. Wei, R. Sun, Y. Moritoki, M. E. Gershwin, Z.-X. Lian, and Z. Tian
CD4+CD25+ Foxp3+ Regulatory T Cells Protect against T Cell-Mediated Fulminant Hepatitis in a TGF-{beta}-Dependent Manner in Mice
J. Immunol., November 15, 2008; 181(10): 7221 - 7229.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. H. Finke, B. Rini, J. Ireland, P. Rayman, A. Richmond, A. Golshayan, L. Wood, P. Elson, J. Garcia, R. Dreicer, et al.
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
Clin. Cancer Res., October 15, 2008; 14(20): 6674 - 6682.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Laronne-Bar-On, D. Zipori, and N. Haran-Ghera
Increased Regulatory versus Effector T Cell Development Is Associated with Thymus Atrophy in Mouse Models of Multiple Myeloma
J. Immunol., September 1, 2008; 181(5): 3714 - 3724.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. B. Heimberger, M. Abou-Ghazal, C. Reina-Ortiz, D. S. Yang, W. Sun, W. Qiao, N. Hiraoka, and G. N. Fuller
Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas
Clin. Cancer Res., August 15, 2008; 14(16): 5166 - 5172.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Gil-Guerrero, J. Dotor, I. L. Huibregtse, N. Casares, A. B. Lopez-Vazquez, F. Rudilla, J. I. Riezu-Boj, J. Lopez-Sagaseta, J. Hermida, S. Van Deventer, et al.
In Vitro and In Vivo Down-Regulation of Regulatory T Cell Activity with a Peptide Inhibitor of TGF-{beta}1
J. Immunol., July 1, 2008; 181(1): 126 - 135.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Vasir, Z. Wu, K. Crawford, J. Rosenblatt, C. Zarwan, A. Bissonnette, D. Kufe, and D. Avigan
Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells
J. Immunol., July 1, 2008; 181(1): 808 - 821.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. S. Sfanos, T. C. Bruno, C. H. Maris, L. Xu, C. J. Thoburn, A. M. DeMarzo, A. K. Meeker, W. B. Isaacs, and C. G. Drake
Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing
Clin. Cancer Res., June 1, 2008; 14(11): 3254 - 3261.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
P. M. Kimball, M. Flattery, F. McDougan, and V. Kasirajan
Cellular Immunity Impaired Among Patients on Left Ventricular Assist Device for 6 Months
Ann. Thorac. Surg., May 1, 2008; 85(5): 1656 - 1661.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. E. C. Lutsiak, Y. Tagaya, A. J. Adams, J. Schlom, and H. Sabzevari
Tumor-Induced Impairment of TCR Signaling Results in Compromised Functionality of Tumor-Infiltrating Regulatory T Cells
J. Immunol., May 1, 2008; 180(9): 5871 - 5881.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Ladoire, L. Arnould, L. Apetoh, B. Coudert, F. Martin, B. Chauffert, P. Fumoleau, and F. Ghiringhelli
Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells
Clin. Cancer Res., April 15, 2008; 14(8): 2413 - 2420.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Yokokawa, V. Cereda, C. Remondo, J. L. Gulley, P. M. Arlen, J. Schlom, and K. Y. Tsang
Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer
Clin. Cancer Res., February 15, 2008; 14(4): 1032 - 1040.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Zhou, L. L'italien, D. Hodges, and X. M. Schebye
Pivotal Roles of CD4+ Effector T cells in Mediating Agonistic Anti-GITR mAb-Induced-Immune Activation and Tumor Immunity in CT26 Tumors
J. Immunol., December 1, 2007; 179(11): 7365 - 7375.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
P. Hubert, N. Jacobs, J.-H. Caberg, J. Boniver, and P. Delvenne
The cross-talk between dendritic and regulatory T cells: good or evil?
J. Leukoc. Biol., October 1, 2007; 82(4): 781 - 794.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
D. Nummer, E. Suri-Payer, H. Schmitz-Winnenthal, A. Bonertz, L. Galindo, D. Antolovich, M. Koch, M. Buchler, J. Weitz, V. Schirrmacher, et al.
Role of Tumor Endothelium in CD4+CD25+ Regulatory T Cell Infiltration of Human Pancreatic Carcinoma
J Natl Cancer Inst, August 1, 2007; 99(15): 1188 - 1199.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
Q. Gao, S.-J. Qiu, J. Fan, J. Zhou, X.-Y. Wang, Y.-S. Xiao, Y. Xu, Y.-W. Li, and Z.-Y. Tang
Intratumoral Balance of Regulatory and Cytotoxic T Cells Is Associated With Prognosis of Hepatocellular Carcinoma After Resection
J. Clin. Oncol., June 20, 2007; 25(18): 2586 - 2593.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Cesana and H. L. Kaufman
In Reply
J. Clin. Oncol., June 20, 2007; 25(18): 2630 - 2632.
[Full Text] [PDF]


Home page
J. Immunol.Home page
K. G. Elpek, C. Lacelle, N. P. Singh, E. S. Yolcu, and H. Shirwan
CD4+CD25+ T Regulatory Cells Dominate Multiple Immune Evasion Mechanisms in Early but Not Late Phases of Tumor Development in a B Cell Lymphoma Model
J. Immunol., June 1, 2007; 178(11): 6840 - 6848.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
V. C. Liu, L. Y. Wong, T. Jang, A. H. Shah, I. Park, X. Yang, Q. Zhang, S. Lonning, B. A. Teicher, and C. Lee
Tumor Evasion of the Immune System by Converting CD4+CD25- T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-beta
J. Immunol., March 1, 2007; 178(5): 2883 - 2892.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Kobayashi, N. Hiraoka, W. Yamagami, H. Ojima, Y. Kanai, T. Kosuge, A. Nakajima, and S. Hirohashi
FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis
Clin. Cancer Res., February 1, 2007; 13(3): 902 - 911.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. J. Bates, S. B. Fox, C. Han, R. D. Leek, J. F. Garcia, A. L. Harris, and A. H. Banham
Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse
J. Clin. Oncol., December 1, 2006; 24(34): 5373 - 5380.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. M. Miller, K. Lundberg, V. Ozenci, A. H. Banham, M. Hellstrom, L. Egevad, and P. Pisa
CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients
J. Immunol., November 15, 2006; 177(10): 7398 - 7405.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Beyer and J. L. Schultze
Regulatory T cells in cancer
Blood, August 1, 2006; 108(3): 804 - 811.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Wei, I. Kryczek, and W. Zou
Regulatory T-cell compartmentalization and trafficking
Blood, July 15, 2006; 108(2): 426 - 431.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Valzasina, S. Piconese, C. Guiducci, and M. P. Colombo
Tumor-Induced Expansion of Regulatory T Cells by Conversion of CD4+CD25- Lymphocytes Is Thymus and Proliferation Independent.
Cancer Res., April 15, 2006; 66(8): 4488 - 4495.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. C. Cesana, G. DeRaffele, S. Cohen, D. Moroziewicz, J. Mitcham, J. Stoutenburg, K. Cheung, C. Hesdorffer, S. Kim-Schulze, and H. L. Kaufman
Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma
J. Clin. Oncol., March 1, 2006; 24(7): 1169 - 1177.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Wolf, A. M. Wolf, H. Rumpold, H. Fiegl, A. G. Zeimet, E. Muller-Holzner, M. Deibl, G. Gastl, E. Gunsilius, and C. Marth
The Expression of the Regulatory T Cell-Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer
Clin. Cancer Res., December 1, 2005; 11(23): 8326 - 8331.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. Baratelli, Y. Lin, L. Zhu, S.-C. Yang, N. Heuze-Vourc'h, G. Zeng, K. Reckamp, M. Dohadwala, S. Sharma, and S. M. Dubinett
Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells
J. Immunol., August 1, 2005; 175(3): 1483 - 1490.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.